Sir,

We read the paper on "Intravenous thrombolysis in a patient with left atrial myxoma with acute ischemic stroke" by Kulkarni GB, Yadav R, Mustare V and Modi S, published in Annals of Indian Academy of Neurology (Ann Indian Acad Neurol 2014;17:455-8)\[[@ref1]\] with great interest.

We congratulate the authors for their efforts in managing this patient. It is commendable on their part to abide by the guidelines in managing a patient who presented with acute ischemic stroke (AIS) in the window period with intravenous thrombolysis.

The fact that she was a known case of left atrial myxoma (LAM), should have been considered prior to thrombolysing her, as fibrinolytic agents cannot lyse myxomatous embolic material. There is no drug treatment for atrial myxoma. The only definite treatment is surgical resection of the tumor.\[[@ref2]\]

Cardiac myxomas are associated with intracranial myxomatous aneurysms in which case the aneurysm may rupture\[[@ref3]\] because of these reasons antithrombotic and anticoagulants are not indicated in AIS associated with atrial myxoma.

These fusiform aneurysms cannot be clipped because they lack a stem, and the only reported treatment is successful surgical excision.\[[@ref4]\] MRI susceptibility-weighted images are three to six times more sensitive than conventional T2-weighted gradient echo images for hemosiderin detection.\[[@ref5]\] This technology can be helpful in detecting "unruptured" aneurysms, when there is a suspicion. Patients with cardiac myxoma should be observed for myxoma-related cerebral aneurysms, which can develop and grow\[[@ref6]\] even after the tumor is resected. Hence, long-term regular follow-up of these patients is recommended.

We wish to reemphasize the fact that thrombolysis with recombinant tissue plasminogen activator (rTPA) is not indicated for myxoma-related AIS and is in fact harmful, and should not be offered to known patients of myxoma presenting with AIS.
